Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Articles|January 1, 2000
The American Journal of Managed Care
- January 2000
- Volume 6
- Issue 1
The Impact of Health Insurance Market Reforms on Market Competition
Author(s)Mark A. Hall, JD
Advertisement
Articles in this issue
almost 27 years ago
Acne Vulgaris: Pathogenesis and Therapeutic Approachalmost 27 years ago
Parkinson's Disease: Focus on Management Alternativesalmost 27 years ago
The Future of Health Status Assessmentalmost 27 years ago
Regulating the Pharmaceutical Industry: Who Really Benefits?almost 27 years ago
Can Peer-Comparison Feedback Improve Patient Functional Status?almost 27 years ago
Preventive Service Use and Medicaid Managed Care in New York CityAdvertisement
Related to this article
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Advertisement
Advertisement
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
Using Complement Inhibitors in GA Comes With Pros and Cons
3
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5